Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InxMed Announces Clinical Collaboration with MSD to Evaluate IN10018 in Combination with Pembrolizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InxMed Released Research Data of \"FAK inhibitor IN10018 Overcomes Drug Resistance of KRAS G12C Inhibition\" at 2020 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"InxMed","sponsor":"Ennovation Ventures","pharmaFlowCategory":"D","amount":"$19.0 million","upfrontCash":"Undisclosed","newsHeadline":"InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"InxMed","sponsor":"Hyfinity Investments","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Fast Track Designation to InxMed's IN10018","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Inxmed IN10018 at ASCO 2022 Demonstrates Robust Efficacy in Patients With Platinum-resistant Recurrent Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"InxMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InxMed Reports Positive Results for Ifebemtinib and Garsorasib in NSCLC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals for Ifebemtinib

    Menu

    Ifebemtinib

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              InxMed

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              InxMed Reports Positive Results for Ifebemtinib and Garsorasib in NSCLC

              Details:

              InxMed investigational product IN10018 (Ifebemtinib), a FAK inhibitor, is being evaluated in combination with garsorasib, for the first-line treatment of non-small cell lung cancer.

              Lead Product(s): Ifebemtinib,Garsorasib

              Therapeutic Area: Oncology Product Name: IN10018

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 30, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              InxMed

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Inxmed IN10018 at ASCO 2022 Demonstrates Robust Efficacy in Patients With Platinum-resistant Recurrent Ovarian Cancer

              Details:

              The data showed that patients receiving combination of IN10018 (BI 853520) with PLD demonstrated promising antitumor activities and manageable safety profile in PROC patients, with a high overall response rate (ORR) of 56.7%.

              Lead Product(s): Ifebemtinib,Pegylated Liposomal Doxorubicin

              Therapeutic Area: Oncology Product Name: BI 853520

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 27, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              InxMed

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers

              Details:

              InxMed will use the funds to accelerate ongoing clinical trials of IN10018 (BI 853520) for multiple cancer types in both US and China, including the initiation of pivotal trials, and advance more stroma targeting pipelines into clinics in both US and China.

              Lead Product(s): Ifebemtinib,Cobimetinib

              Therapeutic Area: Oncology Product Name: BI 853520

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Hyfinity Investments

              Deal Size: $15.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing May 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              InxMed

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              US FDA Grants Fast Track Designation to InxMed's IN10018

              Details:

              Early clinical data of IN10018 has demonstrated a favorable safety profile and promising efficacy signals against a number of tumor types.

              Lead Product(s): Ifebemtinib,Undisclosed

              Therapeutic Area: Oncology Product Name: BI 853520

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 19, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              InxMed

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing

              Details:

              Funding will support the acceleration of IN10018 clinical program and expand InxMed's portfolio. IN10018 is a potent and selective ATP-competitive focal adhesion kinase small molecule inhibitor.

              Lead Product(s): Ifebemtinib,Cobimetinib

              Therapeutic Area: Oncology Product Name: BI 853520

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Ennovation Ventures

              Deal Size: $19.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing September 03, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              InxMed

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              InxMed Released Research Data of "FAK inhibitor IN10018 Overcomes Drug Resistance of KRAS G12C Inhibition" at 2020 AACR Annual Meeting

              Details:

              The combination of KRAS G12C inhibitors and IN10018 induced FAK signaling by KRAS G12C inhibition, serving as one predominant mechanism of drug resistance of KRAS G12C inhibition, and IN10018 significantly decreases the FAK signaling induced by KRAS G12C inhibition.

              Lead Product(s): Ifebemtinib,Cobimetinib

              Therapeutic Area: Oncology Product Name: IN10018

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              InxMed

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018

              Details:

              The trial will include 6 study sites in the U. S and 3 study sites in Australia, and evaluate the safety, tolerability, PK and antitumor activities of IN10018 as monotherapy with Roche's Cobimetinib.

              Lead Product(s): Ifebemtinib,Cobimetinib

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 16, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              InxMed

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              InxMed Announces Clinical Collaboration with MSD to Evaluate IN10018 in Combination with Pembrolizumab

              Details:

              InxMed will be the study sponsor and MSD will provide pembrolizumab to InxMed to use in the clinical study. This is the first global clinical collaboration between the two companies.

              Lead Product(s): Ifebemtinib,Pembrolizumab

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY